Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, et al. Bevacizumab (Avastin(R)) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017.
Article CAS PubMed Google Scholar
Thorell MR, Goldhardt R. Update in the management of macular edema following retinal vein occlusions. Curr Ophthalmol Rep. 2016;4(1):38–47.
Article PubMed PubMed Central Google Scholar
Daruich A, Matet A, Moulin A, Kowalczuk L, Nicolas M, Sellam A, et al. Mechanisms of macular edema: beyond the surface. Prog Retin Eye Res. 2018;63:20–68.
Schmidt-Erfurth U, Pollreisz A, Mitsch C, Bolz M. Antivascular endothelial growth factors in age-related macular degeneration. Dev Ophthalmol. 2010;46:21–38.
Article CAS PubMed Google Scholar
Pang LL, Gan JD, Huang YH, Liao J, Zhuang WT, Ali WA, et al. Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy. BMC Cancer. 2023;23(1):72.
Article CAS PubMed PubMed Central Google Scholar
McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018;24(6):749–57.
Article CAS PubMed PubMed Central Google Scholar
Brandes AA, Bartolotti M, Tosoni A, Poggi R, Franceschi E. Practical management of bevacizumab-related toxicities in glioblastoma. Oncologist. 2015;20(2):166–75.
Article CAS PubMed PubMed Central Google Scholar
Gressett SMSS. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother. 2009;43(3):490–501.
Article CAS PubMed Google Scholar
Tang X, Xu X, Li J, Zhao B. Cardiotoxicity in biological agent-targeted therapy for rheumatoid arthritis: ADR signal mining and analysis of food and drug administration adverse event reporting system database. Front Pediatr. 2021;9:716648.
Article PubMed PubMed Central Google Scholar
Zhao Y, Wang T, Li G, Sun S. Pharmacovigilance in China: development and challenges. Int J Clin Pharm. 2018;40(4):823–31.
Böhm R, von Hehn L, Herdegen T, Klein HJ, Bruhn O, Petri H, Höcker J. OpenVigil FDA - inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications. PLoS One. 2016;11(6):e0157753.
Article PubMed PubMed Central Google Scholar
Higgins JPT, Altman DG, Gtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011:343:d5928.
Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(7):1003–10.
Lipsyc-Sharf M, Ou F, Yurgelun MB, Rubinson DA, Schrag D, Dakhil SR, Stella PJ, Weckstein DJ, Wender DB, Faggen M, Zemla TJ, Heying EN, Schuetz SR, Noble S, Meyerhardt JA, Bekaii-Saab T, Fuchs CS, Ng K. Cetuximab and irinotecan with or without bevacizumab in refractory metastatic colorectal cancer: BOND-3, an ACCRU network randomized clinical trial. Oncologist. 2022;27(4):292–8. https://doi.org/10.1093/oncolo/oyab025.
Article PubMed PubMed Central Google Scholar
Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Awh CC, Kunimoto DY, Marcus DM, Wroblewski JJ, King J, SCORE2 Investigator Group. Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion the SCORE2 randomized clinical trial. JAMA. 2017;317(20):2072–87.
Article CAS PubMed PubMed Central Google Scholar
Gridelli C, de Castro CJ, Dingemans AC, Griesinger F, Grossi F, Langer C, et al. Safety and efficacy of bevacizumab plus standard-of-care treatment beyond disease progression in patients with advanced non-small cell lung cancer: the AvaALL randomized clinical trial. JAMA Oncol. 2018;4(12):e183486.
Article PubMed PubMed Central Google Scholar
Cremolini C, Antoniotti C, Lonardi S, Aprile G, Falcone A. Activity and safety of cetuximab plus modified FOLFOXIRI followed by maintenance with cetuximab or bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a randomized phase 2 clinical trial. JAMA Oncol. 2018;4(4):529–36.
Article PubMed PubMed Central Google Scholar
Brandes AA, Gil-Gil M, Saran F, Carpentier AF, Nowak AK, Mason W, Zagonel V, Dubois F, Finocchiaro G, Fountzilas G, Cernea DM, Chinot O, Anghel R, Ghiringhelli F, Beauchesne P, Lombardi G, Franceschi E, Makrutzki M, Mpofu C, Urban HJ, Pichler J. A Randomized Phase II Trial (TAMIGA) evaluating the efficacy and safety of continuous bevacizumab through multiple lines of treatment for recurrent glioblastoma. Oncologist. 2019;24(4):521–8.
Article CAS PubMed Google Scholar
Akamatsu H, Toi Y, Hayashi H, Fujimoto D, Tachihara M, Furuya N, et al. Efficacy of osimertinib plus bevacizumab vs osimertinib in patients with EGFR T790M-mutated non-small cell lung cancer previously treated with epidermal growth factor receptor-tyrosine kinase inhibitor: West Japan oncology group 8715L phase 2 randomized clinical trial. JAMA Oncol. 2021;7(3):386–94.
Article PubMed PubMed Central Google Scholar
Kulke MH, Ou FS, Niedzwiecki D, Huebner L, Kunz P, Kennecke HF, Wolin EM, Chan JA, O’Reilly EM, Meyerhardt JA, Venook A. Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance). Endocr Relat Cancer. 2022;29(6):335–44.
Article CAS PubMed PubMed Central Google Scholar
Hainsworth JD, Fang L, Huang JE, Karlin D, Russell K, Faoro L, et al. BRIDGE: An open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer. J Thorac Oncol. 2011;6(1):109–14.
Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22(11):2184–91.
Article CAS PubMed Google Scholar
Kurzrock R, Stewart DJ. Exploring the benefit/risk associated with antiangiogenic agents for the treatment of non-small cell lung cancer patients. Clin Cancer Res. 2017;23(5):1137–48.
Article CAS PubMed Google Scholar
Riondino S, Del Monte G, Fratangeli F, Guadagni F, Roselli M, Ferroni P. Anti-angiogenic drugs, vascular toxicity and thromboembolism in solid cancer. Cardiovasc Hematol Agents Med Chem. 2017;15(1):3–6.
Article CAS PubMed Google Scholar
Grechukhina KS, Chebotareva NV, Krasnova TN. Nephrotoxicity of anti-angiogenesis drugs. Terapevticheskii Arkhiv. 2020;92(6):3–8.
Izzedine H, Escudier B, Lhomme C, Pautier P, Rouvier P, Gueutin V, et al. Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center. Medicine (Baltimore). 2014;93(24):333-9.
Vaklavas C, Roberts B, Varley KE, Lin NU, Liu MC, Rugo HS, et al. TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer. Breast Cancer Res. 2020;22(1):22.
Article CAS PubMed PubMed Central Google Scholar
Shah SGS. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother. 2009;43(3):490–501.
Wichelmann TA, Abdulmujeeb S, Ehrenpreis ED. Bevacizumab and gastrointestinal perforations: a review from the FDA Adverse Event Reporting System (FAERS) database. Aliment Pharmacol Ther. 2021;54(10):1290–7.
Article CAS PubMed Google Scholar
Li M, Kroetz DL. Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther. 2018;182:152–60.
Article CAS PubMed Google Scholar
Horowitz JR, Rivard A, van der Zee R, Hariawala M, Sheriff DD, Esakof DD, et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol. 1997;17(11):2793–800.
Article CAS PubMed Google Scholar
Henry TD, Rocha-Singh K, Isner JM, Kereiakes DJ, Giordano FJ, Simons M, et al. Endothelial growth factor to patients with coronary artery disease. Am Heart J. 2001;142:872–80.
Article CAS PubMed Google Scholar
Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation. 2003;107(10):1359–65.
Article CAS PubMed Google Scholar
Coultas L, Chawengsaksophak K, Rossant J. Endothelial cells and VEGF in vascular development. Nature. 2005;438(7070):937–45.
Article CAS PubMed Google Scholar
Eremina VJJ, Kowalewska J, Hochster H, Haas M, Weisstuch J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358:1129–36.
Article CAS PubMed PubMed Central Google Scholar
Ramiscal JA, Jatoi A. Nasal septal perforation from bevacizumab: a discussion of outcomes, management, and pharmacovigilance. Curr Oncol Rep. 2012;14(4):307–10.
留言 (0)